<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936247</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0514</org_study_id>
    <nct_id>NCT00936247</nct_id>
  </id_info>
  <brief_title>Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)</brief_title>
  <official_title>Prospective, Controlled, Single-blind, Bicentric, Randomized Study on the Safety of HES 130/0.42 Combined With a Bal. Electr. Sol. vs 5% Albumin Comb. With an Unbal. Electr. Sol. (NaCl 0.9%) in Pat. With Compensated Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigational study will investigate two different volume replacement regimes in
      patients suffering from compromised renal function.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    organizational reasons at sites: low recruitment
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of two different volume replacement regimes on base excess in patients with reduced renal function</measure>
    <time_frame>from pre-operative assessment until last evaluation of data i.e. 5th (hospital) and 60th postoperative day (follow-up)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function, hemodynamics, blood loss, amount of given blood products, electrolytes, outcome and other data like concomitant medication</measure>
    <time_frame>inta-/postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HES 130/0.42 + Sterofundin ISO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albumin + NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HES 130/0.42 + electrolyte solution</intervention_name>
    <description>Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin + electrolyte solution</intervention_name>
    <description>Albumin 5% as colloid component and NaCl 0.9% as electrolyte component</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  male or female patients

          -  ≥ 50 years of age;

          -  patients with compromised renal function, i.e. serum creatinine between 1.5 mg/dl and
             3.0 mg/dl;

          -  patients scheduled for elective intervention;

          -  patients with an estimated intraoperative volume need of at least 1 l colloids;

          -  provision of voluntary informed consent to participate in the study, following a full
             explanation of the nature and purpose of the study, by signing the informed consent
             form approved by the Institutional Ethics Committee (IEC) prior to all evaluations

        Exclusion:

          -  patients of ASA-class &gt; III;

          -  patients with daily urine output &lt; 1 l;

          -  patients on haemodialysis;

          -  patients receiving HES during the last 48 hours before first infusion of the
             investigational products;

          -  patients suffering from coagulation disorders (i.e. PTT &gt; 60 sec);

          -  patients with a hemoglobin &lt; 9 g/dl;

          -  patients with known hypersensitivity to HES, albumin or any of the excipients;

          -  patients suffering from contraindications of the investigational products (i.e.
             hyperhydration state including pulmonary oedema, renal failure with oliguria or
             anuria, intracranial haemorrhage, hyperkalaemia, severe hypernatraemia or severe
             hyperchloraemia, severely impaired hepatic function, congestive heart failure);

          -  simultaneous participation in another clinical trial; emergencies;

          -  patients scheduled for brain surgery;

          -  patients incapable to give informed consent (e.g. patients with dementia, psychiatric
             diseases or suffering from conditions associated with lack of consciousness)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lücke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Mannheim gGmbH, Klink für Anästhesiologie und Operative Intensivmedizin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie und operative Intensivmedizin, Klinikum der Stadt Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim gGmbH, Klinik für Anästhesiologie und Operative Intensivmedizin</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2009</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Simone Arnold</name_title>
    <organization>B. Braun Melsungen AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

